| Old Articles: <Older 2851-2860 Newer> |
|---|
 |
Managed Care
April 2006 |
Pay-for-Performance Champions Excited by California Program's Success A quality incentive program in California is yielding results that could be replicated in Medicare and other pay-for-performance (P4P) programs nationwide according to a new report.   |
Managed Care
April 2006 |
Fewer New Therapies Expected for GI Disorders by 2010 Will prescription drugs for gastrointestinal disorders go the way antihistamine medications did when the FDA approved a generic version of Claritin in 2002? |
BusinessWeek
May 8, 2006
Catherine Arnst |
Hey, You Don't Look So Good As diagnoses of once-rare illnesses soar, doctors say drugmakers are "disease-mongering" to boost sales. |
IndustryWeek
May 1, 2006
Jonathan Katz |
St. Louis: Gateway For New Medicines Considering the St. Louis region a strategic location for developing new drugs, Pfizer Inc. has consolidated its R&D operations there for greater collaboration. |
The Motley Fool
April 26, 2006
Stephen D. Simpson |
A Pain DOV Pharmaceutical Couldn't Cure A trial failure crushes the stock, but the game isn't over yet. Though there are risks aplenty here, there could still be value. |
The Motley Fool
April 25, 2006
Brian Gorman |
Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain. |
The Motley Fool
April 24, 2006
John Bluis |
Affymetrix Gets Chipped Again The woes continue for Affymetrix, the leading provider of high-density microarray products. Investors must decide if this is a management issue -- as indeed it appears to be. |
InternetNews
April 21, 2006
Tim Scannell |
An Active Hand in The Healing Process Hospitals are turning to the Internet and remote reporting technologies to get patients more involved in medical decision-making. |
BusinessWeek
May 1, 2006
Howard Gleckman |
Medicare Surprise Why many seniors could temporarily lose drug coverage. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Wait for More Bad News on Merck Vioxx lawsuits will be an ever-present headline risk for a while, but I still believe it's highly unlikely that they'll do lasting damage to the business. That said, the nearly 30% rise in this stock since late '05 has taken a lot of the easy money off the table. |
| <Older 2851-2860 Newer> Return to current articles. |
